By james art WINSTON-SALEM, NC / ACCESSWIRE / October 23, 2024 / Postbiotics, Inc. and Sabinsa Corporation announced today a multinational distribution agreement (including the US, Canada, the European Union and other significant markets (including India and Japan)) for the dietary supplement and functional food ingredient PoZibio® for age-related digestive health conditions, including Leaky Gut Syndrome ( LGS).
Postbiotics, Sabinsa, PoZibio
PoZibio® is a patent-protected postbiotic composition of Lactobacillus paracasei (Patent number US 11,622,981 B2). Discovered by gut microbiome longevity researchers at Wake Forest University College of Medicine, the ingredient is suitable for use in functional foods, medical foods and dietary supplements due to its low dosage, heat stability and neutral flavor profile.
Shaheen Majeed, Global CEO and Managing Director of Sabinsa, said: “I am delighted to introduce an ingredient for a condition that is very under-addressed in the market. Furthermore, this marks one of the first partnerships that Sabinsa has entered into globally, and at its core represents the best of science and functionality.”
Doug Lynch, Co-Founder and Chief Commercial Officer of Postbiotics, Inc., stated, “We are delighted to be working with Sabinsa and believe their global sales organization and manufacturing capabilities are perfect complements to our world-class research.”
Hariom Yadav, MD, associate professor of neurosurgery and brain rehabilitation and director of the University of South Florida’s Center for Microbiome Research, who discovered PoZibio while at Wake Forest, stated that “The benefits to the gut-brain axis that we showed from PoZibio®, are fascinating. PoZibio® has been shown to increase the lining of the gut wall, inhibit age-related inflammation (inflammation), support cognitive function, and promote muscle and metabolic health, in previous and ongoing studies.
About Sabinsa Corporation
Sabinsa, founded by the late Dr. Muhammad Majeed in 1988, is a manufacturer and supplier of standardized herbal extracts, nutritional and cosmeceutical ingredients, probiotics, minerals, enzymes and specialty and fine chemicals. The company markets more than 120 standardized botanical extracts and employs more than 1,800 people worldwide in 27 manufacturing, research and development, sales and distribution facilities. Process development and product innovation form the focus of ongoing research and development efforts at the company’s research facilities located in India and the US. The products, many of which are kosher and halal, are extensively researched, patented and backed by hundreds of published clinical studies. Sabinsa’s botanical cultivation program totals nearly 20,000 acres to ensure that sustainable, fair trade materials are used in these ingredients. For more information, visit www.sami-sabinsagroup.com.
About Postbiotics, Inc. (PBI)
Postbiotics, Inc., commercialized research at Wake Forest College of Medicine. PBI develops medical foods to improve health and support the dietary management of IBD/IBS and therapy-induced inflammatory response. PBI also develops dietary supplement ingredients that target the negative effects associated with leaky gut syndrome (LGS), a normal part of aging. PBI’s lead ingredient, patent-protected PoZibio®, supports the gut-brain axis, nutrient absorption, cognition, mood, mitochondrial function and enhanced immunity in humans and animals. For information, visit www.postbioticsinc.com.
Contact information
Douglas Lynch
Marketwell Nutrition Inc
[email protected]
1 609-977-8953
SOURCE: Postbiotics, Inc
See the original press release at newswire.com.